Tresperimus (Laboratoires Fournier).
Tresperimus (LF-08-0299) is an immunosuppressant under development by Laboratoires Fournier for its potential use in organ transplant rejection. Fournier has commenced phase III trials in the US and Europe [304203]. Tresperimus began phase I/II trials in 1995 for graft versus host rejection in combination with cyclosporine and tacrolimus, but later as first-line therapy. It demonstrated efficient immunosuppressive activity in a rat model of cardiac rejection [182951]. The company is seeking licensees for the product
Elices
M J
MJ
carmarel@earthlink.net
D000818:Animals; D002219:Carbamates / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D005544:Forecasting; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015394:Molecular Structure; D011239:Prednisolone / Q000627:therapeutic use
D002219:Carbamates; D015507:Drugs, Investigational; D007166:Immunosuppressive Agents; C092303:tresperimus; D011239:Prednisolone